TNBC is associated with an aggressive course and poor survival, and unlike patients with ER/PR‐positive or HER2‐overexpressing breast cancer, TNBC is not amenable to hormone therapy or HER2‐targeting therapy, such as trastuzumab 3, 4, 5. The gene discussed is ESR1; the disease is breast carcinoma.